ArticleFrontiers in medicine2025
Correlation between serum autotaxin levels and optic neuropathy in early diabetic retinopathy: a case-control study.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To explore the correlation between serum autotaxin (ATX) levels and optic neuropathy in early diabetic retinopathy (DR). Methods: A total of 90 patients with early DR who were treated in our hospital from August 2022 to December 2023 were selected as the Non diabetic neuropathy (NDN) group, and another 90 patients with early DR combined with optic neuropathy were selected as the combined diabetic neuropathy (DN) group. In addition 90 healthy patients were selected as a normal control group. The general data of the two groups of patients were collected, and the levels of inflammatory factors were compared, including the platelet-to-lymphocyte ratio (PLR), neutrophil-to-lymphocyte ratio (NLR), lymphocyte-to-monocyte ratio (LMR), systemic inflammation response index (SIRI), platelet-to-albumin ratio (PAR), serum C-reactive protein (CRP), tumor necrosis factor-α (TNF-α), and interleukin-6 (IL-6). The levels of ATX, glial fibrillary acid protein (GFAP), and neurofilament light chain protein (NfL) were also compared between the two groups. Retinal OCT examination was performed in both groups to record the foveal avascular zone (FAZ) area, acircularity index (AI), mean RNFL thickness at the disk margin, temporal, superior, nasal, and inferior, and mean macular ganglion cell inner plexiform layer (mGCIPL) thickness and vascular density (VD) levels. Pearson analysis was used to analyze the correlation between ATX and inflammatory factors, GFAP, NfL, mGCIPL, and VD levels. Multivariate Logistic regression analysis was used to analyze the influencing factors of optic neuropathy in DR patients. ROC curve analysis was used to analyze the clinical value of ATX in diagnosing optic neuropathy in DR patients. Results: There were no significant differences in PLR, NLR, LMR, PAR, SIRI index, serum TNF-α, CRP, and IL-6 levels between the healthy group, the NDN group and the combined DN group ( Conclusion: The increase of serum ATX content may be involved in the occurrence and development of optic neuropathy in DR, and has a significant correlation with early neurological and vascular changes in the early stage of the disease. Measuring serum ATX levels may aid in the early diagnosis of optic neuropathy in DR and provides new ideas for its treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.